Alnylam Pharmaceuticals (NASDAQ:ALNY) Coverage Initiated at Redburn Atlantic

Research analysts at Redburn Atlantic initiated coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research note issued to investors on Monday, Marketbeat reports. The firm set a “buy” rating and a $353.00 price target on the biopharmaceutical company’s stock. Redburn Atlantic’s price objective suggests a potential upside of 38.02% from the stock’s current price.

A number of other research firms have also recently issued reports on ALNY. Sanford C. Bernstein dropped their price objective on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Royal Bank of Canada lifted their price target on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an “outperform” rating in a research note on Friday, March 21st. Citigroup lifted their price objective on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a “buy” rating in a report on Friday, March 21st. Stifel Nicolaus upped their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Morgan Stanley increased their target price on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. One analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $316.25.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $255.76 on Monday. The firm has a market capitalization of $33.27 billion, a price-to-earnings ratio of -117.86 and a beta of 0.39. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The business has a 50 day simple moving average of $260.15 and a 200-day simple moving average of $260.51. Alnylam Pharmaceuticals has a 1 year low of $141.98 and a 1 year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Equities analysts forecast that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CMO Pushkal Garg sold 52,592 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the sale, the chief marketing officer now owns 11,989 shares of the company’s stock, valued at $3,416,865. The trade was a 81.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Phillip A. Sharp sold 11,250 shares of the company’s stock in a transaction on Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total transaction of $3,093,750.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 71,234 shares of company stock worth $19,958,097. Company insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Larson Financial Group LLC grew its position in Alnylam Pharmaceuticals by 187.2% during the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 73 shares during the period. Park Square Financial Group LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $28,000. R Squared Ltd purchased a new position in shares of Alnylam Pharmaceuticals during the 4th quarter valued at approximately $33,000. OFI Invest Asset Management acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at $35,000. Finally, Colonial Trust Co SC purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $35,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.